BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18243408)

  • 1. The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients.
    Duarte RL; Luiz RR; Paschoal ME
    Lung Cancer; 2008 Aug; 61(2):244-54. PubMed ID: 18243408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance with adjuvant chemotherapy in non-small cell lung cancer. The experience of a single institution evaluating a cohort of 356 patients.
    Dediu M; Alexandru A; Median D; Anghel R; Tarlea A; Iorga P; Movanu M
    J BUON; 2006; 11(4):425-32. PubMed ID: 17309173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
    Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer.
    Zhang Z; Xu F; Wang S; Li N; Wang C
    Lung Cancer; 2008 Jun; 60(3):434-40. PubMed ID: 18036699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
    Dediu M; Horvat T; Tarlea A; Anghel R; Cordos I; Miron G; Iorga P; Alexandru A; Nistor C; Grozavu C; Savu C
    Lung Cancer; 2005 Jan; 47(1):93-101. PubMed ID: 15603859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking intensity, oxidative stress and chemotherapy in nonsmall cell lung cancer: a correlated prognostic study.
    Gupta A; Srivastava S; Prasad R; Natu SM; Mittal B; Negi MP; Srivastava AN
    Biosci Trends; 2009 Oct; 3(5):191-9. PubMed ID: 20103846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers.
    Toh CK; Gao F; Lim WT; Leong SS; Fong KW; Yap SP; Hsu AA; Eng P; Koong HN; Thirugnanam A; Tan EH
    Lung Cancer; 2007 May; 56(2):161-6. PubMed ID: 17270313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival.
    Videtic GM; Stitt LW; Dar AR; Kocha WI; Tomiak AT; Truong PT; Vincent MD; Yu EW
    J Clin Oncol; 2003 Apr; 21(8):1544-9. PubMed ID: 12697879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
    Tsao AS; Liu D; Lee JJ; Spitz M; Hong WK
    Cancer; 2006 Jun; 106(11):2428-36. PubMed ID: 16634096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
    Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy.
    Kawaguchi T; Matsumura A; Iuchi K; Ishikawa S; Maeda H; Fukai S; Komatsu H; Kawahara M
    Jpn J Clin Oncol; 2006 Jan; 36(1):7-11. PubMed ID: 16368713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study.
    Kim JH; Kim HS; Kwon JH; Park S; Kim HY; Jung JY; Kim HJ; Song HH; Lee GW; Lee SI; Gong SJ; Lee JA; Kim KJ; Zang DY
    Lung Cancer; 2009 Mar; 63(3):405-9. PubMed ID: 18621432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
    Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
    Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.
    Oshita F; Ikehara M; Sekiyama A; Hamanaka N; Saito H; Yamada K; Noda K; Kameda Y; Miyagi Y
    J Exp Ther Oncol; 2004 Jul; 4(2):155-60. PubMed ID: 15500010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.